ronstik_AdobeStockThis week, Psychiatric Times® discussed a wide variety of psychiatric issues and industry updates, from the FDA’s decision about MDMA-assisted therapy to a look at the new data on seltorexant for MDD and insomnia. Panel experts weighed the need for new PTSD treatments against the concerns with data submitted by Lykos Therapeutics. Andrew Krystal, MD: It should be routine for all clinicians to assess for insomnia among patients being evaluated or treated for depression. Continue ReadingSee more recent coverage from Psychiatric Times here. And be sure to stay up-to-date by subscribing to the Psychiatric Times E-newsletter.

Source: CNN June 08, 2024 13:04 UTC